Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.

Mengelbier LH, Karlsson J, Lindgren D, ├śra I, Isaksson M, Frigyesi I, Frigyesi A, Bras J, Sandstedt B, Gisselsson D.

Am J Pathol. 2010 Nov;177(5):2609-21. doi: 10.2353/ajpath.2010.100130. Epub 2010 Sep 16.

2.

Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM; National Wilms Tumor Study Group.

J Clin Oncol. 2005 Oct 10;23(29):7312-21. Epub 2005 Aug 29.

PMID:
16129848
3.
4.

Hemizygous deletions of chromosome band 16q24 in Wilms tumor: detection by fluorescence in situ hybridization.

Shearer PD, Valentine MB, Grundy P, DeCou JM, Banavali SD, Komuro H, Green DM, Beckwith JB, Look AT.

Cancer Genet Cytogenet. 1999 Dec;115(2):100-5.

PMID:
10598141
5.

Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.

Grundy P, Telzerow P, Moksness J, Breslow NE.

Med Pediatr Oncol. 1996 Nov;27(5):429-33.

PMID:
8926924
6.

SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.

Sehic D, Karlsson J, Sandstedt B, Gisselsson D.

Pediatr Blood Cancer. 2012 Jul 15;59(1):62-8. doi: 10.1002/pbc.24025. Epub 2011 Dec 16.

PMID:
22180226
7.

Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.

Safford SD, Freemerman AJ, Langdon S, Bentley R, Goyeau D, Grundy PE, Skinner MA.

J Pediatr Surg. 2005 Feb;40(2):341-8.

PMID:
15750927
8.

Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.

Safford SD, Goyeau D, Freemerman AJ, Bentley R, Everett ML, Grundy PE, Skinner MA.

Ann Surg Oncol. 2003 Mar;10(2):136-43.

PMID:
12620908
9.

Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K, Jones C.

Cancer Res. 2006 Dec 1;66(23):11148-55.

10.

Identical genetic changes in different histologic components of Wilms' tumors.

Zhuang Z, Merino MJ, Vortmeyer AO, Bryant B, Lash AE, Wang C, Deavers MT, Shelton WF, Kapur S, Chandra RS.

J Natl Cancer Inst. 1997 Aug 6;89(15):1148-52.

PMID:
9262253
11.

RNA expression of the WT1 gene in Wilms' tumors in relation to histology.

Miwa H, Tomlinson GE, Timmons CF, Huff V, Cohn SL, Strong LC, Saunders GF.

J Natl Cancer Inst. 1992 Feb 5;84(3):181-7.

PMID:
1311774
12.

16q heterozygosity loss in Wilms' tumour in children and its clinical importance.

Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Debiec-Rychter M.

Eur J Surg Oncol. 2000 Feb;26(1):61-6.

PMID:
10718182
13.

Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene.

Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B.

Genes Chromosomes Cancer. 2002 Oct;35(2):156-63.

PMID:
12203779
14.

Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.

Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M.

Genes Chromosomes Cancer. 2007 Feb;46(2):163-70.

PMID:
17099873
15.

Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.

Spreafico F, Ciceri S, Gamba B, Torri F, Terenziani M, Collini P, Macciardi F, Radice P, Perotti D.

Oncotarget. 2016 Feb 23;7(8):8908-15. doi: 10.18632/oncotarget.6950.

16.

Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.

Ohshima J, Haruta M, Arai Y, Kasai F, Fujiwara Y, Ariga T, Okita H, Fukuzawa M, Hata J, Horie H, Kaneko Y.

Genes Chromosomes Cancer. 2009 Dec;48(12):1037-50. doi: 10.1002/gcc.20705.

PMID:
19760604
17.

Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.

Re GG, Willingham MC, el Bahtimi R, Brownlee NA, Hazen-Martin DJ, Garvin AJ.

Mod Pathol. 1997 Feb;10(2):129-36.

PMID:
9127318
18.

Identification of the IRXB gene cluster as candidate genes in severe dysgenesis of the ocular anterior segment.

Chaabouni M, Etchevers H, De Blois MC, Calvas P, Waill-Perrier MC, Vekemans M, Romana SP.

Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4380-6. doi: 10.1167/iovs.09-4111. Epub 2010 Feb 17.

PMID:
20164457
19.

Evaluation of CITED1, SIX1, and CD56 protein expression for identification of blastemal elements in Wilms tumor.

Sehic D, Ciornei CD, Gisselsson D.

Am J Clin Pathol. 2014 Jun;141(6):828-33. doi: 10.1309/AJCPQ8Q0YTHSYZTX.

PMID:
24838327
20.

Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.

Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K.

Genes Chromosomes Cancer. 2011 Dec;50(12):982-95. doi: 10.1002/gcc.20907. Epub 2011 Aug 31.

PMID:
21882282

Supplemental Content

Support Center